Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII

Inclusion Criteria: * Patient with symptomatic de novo coronary lesion involving one or two vessels * Patient presenting a lesion with \> 50% stenosis * Patient who must undergo a percutaneous coronary intervention (PCI) in the indications of Cobalt-chromium bare metal stents and TITAN2 stents and being able to be indifferently treated with one or the other of these stents. * Written informed consent * Expected survival \> 2 years * Patient reachable by phone throughout the duration of the study. Exclusion Criteria: * Pregnant/Lactating women * Women of childbearing potential (last menstrual period \<12 months) not using effective contraception * Patient under legal protection * Indication of coronary artery bypass graft surgery (CABG) * History of coronary artery bypass graft surgery (CABG) * Intrastent restenosis lesion * Bifurcation lesion with the exception of those treated with a standardized approach (provisional stenting with final kissing in the side branch) * Left main coronary lesion * Ostial target lesion * Previous drug-eluting stenting * Previous bare metal stenting or balloon angioplasty in the 12 months prior the inclusion; if this implantation involved the target artery, separate the new implanted stent at a distance ≥ 10 mm. * History of stent thrombosis * Heavily calcified lesion * Use of the Rotablator * Left ventricular ejection fraction (LVEF) \< 30% * Cardiac arrest, cardiogenic shock or severe heart failure (Killip stage III or IV) * Severe chronic renal failure (creatinine clearance \<30 ml min) * Cardiac or renal transplantation * Major surgery within the last 14 days * Surgery scheduled within 30 days (non-ACS patients) or 12 months (if ACS) at the time of the randomization * History of major bleeding * Pathology with major risk of bleeding or any condition, allergy or intolerance which is incompatible with anticoagulation and / or extended antiplatelet therapy * Known allergy to Titanium, Nickel, Cobalt or Chromium * Patient currently participating in another clinical trial * Non-compliant patient (treatment and follow-up) * Patient living abroad